NASDAQ:ETON Eton Pharmaceuticals Q1 2024 Earnings Report $16.60 -0.37 (-2.20%) Closing price 03:59 PM EasternExtended Trading$16.53 -0.07 (-0.40%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Eton Pharmaceuticals EPS ResultsActual EPS-$0.03Consensus EPS -$0.02Beat/MissMissed by -$0.01One Year Ago EPS-$0.10Eton Pharmaceuticals Revenue ResultsActual Revenue$7.97 millionExpected Revenue$8.30 millionBeat/MissMissed by -$330.00 thousandYoY Revenue GrowthN/AEton Pharmaceuticals Announcement DetailsQuarterQ1 2024Date5/9/2024TimeAfter Market ClosesConference Call DateThursday, May 9, 2024Conference Call Time4:30PM ETUpcoming EarningsEton Pharmaceuticals' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Tuesday, May 13, 2025 at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Eton Pharmaceuticals Q1 2024 Earnings Call TranscriptProvided by QuartrMay 9, 2024 ShareLink copied to clipboard.There are 4 speakers on the call. Operator00:00:00Good afternoon, and welcome to the Eaton Pharmaceuticals First Quarter 2024 Financial Results Conference Call. At this time, all participants are in listen only mode. Following the formal remarks, we will open the call up for your questions. Please be advised that this call is being recorded at the company's request. At this time, I'd like to turn it over to David Krimpa, Chief Business Officer at Eton Pharmaceuticals. Operator00:00:27Please proceed. Speaker 100:00:33Thank you, operator. Good afternoon, everyone, and welcome to Eaton's Q1 2024 Conference Call. This afternoon, we issued a press release that outlines the topics we plan to discuss on today's call. The release is available on our website, eatonpharma.com. Joining me on our call today, we have Sean Brynjelsen, our CEO and James Gruber, our CFO. Speaker 100:00:55In addition to taking live questions on today's call, we will be answering questions that are emailed to us. Investors can send their questions to investorrelationseatonpharma.com. Before we begin, I would like to remind everyone that remarks made during this call may contain forward looking statements and involve risks and uncertainties that could cause actual results to differ materially from those contained in these forward looking statements. Please see the forward looking statements disclaimer in our earnings release and the risk factors in the company's filings with the SEC. Now, I will turn the call over to our CEO, Sean Brynjelsen. Speaker 100:01:37Thank you, David. Good afternoon, everyone, and thank you for joining us today. After a strong finish to 2023, I am pleased to say we carry this momentum into 2024 delivering our 13th straight quarter of sequential product revenue growth. It has been a very productive start to 2024 for the company and we have a number of exciting items to discuss today. In addition to posting record revenue sales in Q1, we also acquired a new commercial growth asset in PKU Go Like. Speaker 100:02:08We launched meticinone capsules and more importantly, Eaton submitted our new drug application for ET-four hundred. We were pleased to deliver another quarter of strong revenue growth and to do so while maintaining our disciplined cost structure. Revenue from product sales grew by more than 50% year over year to $8,000,000 while our SG and A spending actually declined by 4% year over year. As you can see, now that we have our infrastructure in place, there was significant operating leverage in our business. We believe we could support a revenue level in many multiples over our current run rate with only a modest increase in our SG and A spending. Speaker 100:02:47This should allow us to deliver substantial earnings as we scale our revenue towards our goal of being a $100,000,000 plus revenue company in the coming years. Our record product sales in the quarter were driven primarily by strong growth in both kaglumic acid and alchemia sprinkle. I remain very encouraged by the trajectory of our kaglumic acid product as it continues to exceed our expectations. We believe we have now captured more than 50% of the patient population, but the product continues to grow and we have added additional patients in Q1 and also additional ones in Q2. Kerglumik is a part of our metabolic portfolio that expanded from 2 products to 4 products in the Q1 as we launched metasalone capsules and acquired PKU Golide. Speaker 100:03:33As you may know, metasalone capsules launched in February and we were able to add a number of patients before the end of the quarter. The market for neticinone is estimated to be around $50,000,000 annually, but there are already a number of competitors in the market, so we have modest expectations for this product. We view the opportunities similar to the way we view Betaine. Neither one offers a large revenue opportunity on its own, but they require very little incremental expense to commercialize since we already have the metabolic infrastructure in place. Perhaps more importantly, the expanded portfolio helps us strengthen our relationship and increase the frequency of interactions with high value kerglumic acid prescribers. Speaker 100:04:15And now with our recent goal like acquisition, natisonone and betaine can help drive additional opportunities to cross sell goal like, which I will spend a few minutes talking about. I was very excited to close this acquisition in March and I believe it adds another compelling growth asset to our metabolic portfolio. Golike is a medical formula for patients with phenylketonuria, also known as PKU. PKU patients like the enzyme needed to break down phenylalanine, which is an amino acid found in protein. For these patients, eating protein results in the buildup of phenylalanine, which can cause neurological problems, including seizures and brain damage. Speaker 100:04:53As a result, many of these PKU patients must take specialized no or low protein medical formulas such as PKU GoLike. Just like our other metabolic products, GoLike is distributed by a specialty distributor that handles dispensing and patient support. The product is typically covered by insurance and it is prescribed by healthcare professionals. I believe GoLike is a compelling opportunity and I'm excited about it for a number of reasons. First, GoLike is very strategic fit with our corporate strategy and commercial infrastructure. Speaker 100:05:26The product serves an ultra orphan population of an estimated 8,000 PKU patients in the United States. These patients rely on medical formulas and the condition is managed by metabolic geneticists and their support staff, the same healthcare professionals that we are actively engaged with on our other metabolic products. Secondly, GoLike is an attractive product that we believe has significant advantages over the competition. Historically, PKU patients have relied on medical providers or medical powders that must be mixed and drank multiple times each day as meal replacements. GOL Like has a number of benefits. Speaker 100:06:02It comes in a convenient and ready to eat bar format. We believe it is significantly is better smelling than competitor products and it is a patented delayed release amino acid technology designed to keep patients full for longer periods of time. And finally, GoLike offered a compelling financial opportunity. We paid less than 2x annual revenue for the product and expect to see significant revenue growth for years to come. Golike Granules were launched at the end of 2022 and Golike Bars were launched in mid-twenty 23. Speaker 100:06:35So the product is still in its infancy stages of launch. We believe our larger commercial footprint and existing relationships with the metabolic community can help accelerate the product's adoption. The U. S. Market for PKU GoLite medical formulas is estimated to be approximately $100,000,000 annually. Speaker 100:06:55With GOL Life's attractive product benefits and our commercial infrastructure, our goal is to capture at least 10% market share or $10,000,000 annually in the coming years. Our sales team launched the product under Eton's ownership at the Metabolic Dieticians International Conference in mid April and we received very strong interest and positive feedback from the dietitian community at the conference. This further reinforced our belief that GoLike provides an improved patient experience and should see significant growth in the years to come as we raise awareness and education in the community. Switching now to the endocrinology side of our business. Alkendi Sprinkle also posted record sales and significant growth in the quarter. Speaker 100:07:38As we discussed in our previous call, we recently introduced a sampling program and our commercial team has been very active at medical conferences so far this year, including exhibiting at the Pediatric Endocrine Society meeting last week. We have seen growth in new patient prescriptions so far and most patients who try Alkindi have a positive experience and remain on therapy. Eaton does however continue to see patients that choose to discontinue treatment due to the texture of the granules. As Okeindi continues to grow, we have a number of initiatives underway to lessen this discontinuation rate, including revamping our educational and administrative materials, but we also believe ET-four hundred will most adequately address this issue. In addition to reducing discontinuation, ET-four hundred will provide an important treatment alternative to the large contingent of patients that use a liquid product today, either a suspension formulation from a compounder that is not FDA approved or their own version that they make at home by crushing tablets and mixing them with water or have been resistant to alkeny sprinkle because they want to stay with a liquid dosage form. Speaker 100:08:44We believe that this portion of the population, which could include several 1,000 patients will be pleased with the accurate dosing in the liquid form that ET-four hundred will provide once it is approved. On our last call, I mentioned that we had passed our clinical study, which was the final hurdle in submission of the ET-four hundred NDA. I am now thrilled to say that we submitted the NDA last week. We anticipate that the FDA will assign the application a 10 month review, allowing for potential approval during the Q1 of 2025. Our team has begun preparing launch activities in order to be in a position to efficiently and effectively commercialize the product shortly after approval. Speaker 100:09:24I remain confident that once approved, the commercialization of ET-four hundred will significantly accelerate the company's growth trajectory and we believe that ET-four hundred and ALK kidney Sprinkle will achieve combined peak sales of over $50,000,000 annually. We also continue to make progress with ET-six hundred, a product candidate under development for the treatment of diabetes ET-six hundred is another new pediatric endocrinology product that we hope to launch soon after ET-four hundred. The product was passed as pilot bioequivalency study and we are on track to run a pivotal study in the second half of this year. Our team expects to submit the NDA in early 2025 for potential approval near the end of 2025. I think it is clear that our 5 commercial products plus our attractive late stage pipeline position us well for sustained long term growth. Speaker 100:10:16That being said, we continue to look for business development opportunities that can propel us even further. Our business development team is currently focused on commercial revenue generating products. Our available capital positions us for a large value creating acquisition. And given our current valuation and expected growth, we would intend to use primarily debt for any such acquisition. As an example of our capacity, in April, we were the runner-up bidder in the bankruptcy auction for Iger Biopharmaceuticals' Zokinbi product. Speaker 100:10:47While we did not we were able to quickly arrange committed capital within a matter of days to support a $46,000,000 bid. While we submitted a competitive offer for the asset, at the end of the day, we are not interested in overpaying for any asset. Given our attractive current financial position, our strong organic growth potential and the expectation for ET-four hundred to deliver significant tailwind next year, we have the luxury of being able to remain extremely disciplined on M and A. While we would like to add a larger asset to the product portfolio, I am cautiously optimistic that we can do so. We certainly do not need to. Speaker 100:11:24Our existing portfolio and pipeline positions us to reach our profitability goals in the coming years. And with that, I'll turn it over to James, our Chief Financial Officer, to to discuss the financials. James? Speaker 200:11:38Thank you, Sean. Our first quarter revenue was 8,000,000 dollars compared to $5,300,000 in the Q1 of 2023, an increase of 50%. In both periods, revenue was comprised entirely of product sales and royalties and the increase was primarily due to increased sales volume of our Arkindi sprinkle and kardalumic acid products. We expect product sales to continue to grow quarter over quarter throughout the rest of this year and beyond. Gross profit for the quarter was $5,000,000 compared with $3,300,000 in the prior year period. Speaker 200:12:16R and D expenses for the quarter were $700,000 compared with $500,000 in the prior year period, and the increase was primarily due to development activities related to ET-four hundred. While we expect an increase in 2nd quarter R and D expenses with a $2,000,000 filing fee for ET-four hundred, we expect total R and D spend for 2024 to remain at approximately 4,000,000 dollars excluding the one time filing fee. General and administrative expenses for the quarter were $5,200,000 compared with $5,300,000 in the prior year period with the decrease due to a slight reduction in employee related expenses and logistics costs. We expect general and administrative expenses to remain relatively constant throughout the remainder of 2024 even with the recent PKU Go Like acquisition and neticinone launch. Total company net loss was $800,000 for the quarter compared to a net loss of $2,700,000 in the prior year period. Speaker 200:13:21Net loss per basic and diluted share was $0.03 during the quarter compared to a net loss per basic and diluted share of $0.10 in the prior year period. Given our current expectations surrounding the timing of R and D activities, we expect to report positive quarterly net income by the end of this year. Eaton finished the Q1 with $16,700,000 of cash on hand and our operating cash burn during the quarter was 2,500,000 dollars While we achieved positive operating cash flow in the second half of twenty twenty three, the Q1 of 2024 was impacted by a one time milestone payment of $1,000,000 related to 2023 al Kindi Sprinkle sales achievement, a payment of $500,000 for inventory associated with the PKU Go Like product acquisition and by the calendarization of marketing and promotion spent that is heavily weighted in the first half of the year. We remain confident that our continued sales growth and disciplined cost structure will result in positive operating cash flow throughout the remainder of 2024 and allow us to actively pursue new product opportunities. This concludes our remarks on Q1 results. Speaker 200:14:39And with that, I'll turn it over to the operator for Q and A. Operator00:14:44Thank you. At this time, we will conduct a question and answer session. First question comes from the line of Chase Knickerbocker of Craig Hallum. Your line is now open. Speaker 300:15:13Good afternoon, guys. Thanks for taking the questions. I'm just going to kind of go product line by product line here. Maybe just to start on Carglumac, Sean. Where are we at in that product's lifecycle? Speaker 300:15:25Do you think we can add a couple handfuls of patients this year still? Or should we think about it as you kind of maintaining the patient volumes that you have, say, in 1Q kind of through this year? Speaker 100:15:39Well, hi, Chase. There's still some runway apparently. We continue to add patients. We just added 3 more patients for the past week. And our estimate is there's up to 100 patients. Speaker 100:15:54We have about a little more than half of that and it continues to grow. We get a lot of new patients on, which actually tend to use that same product over extended period of time. In terms of the product life, it has been robust it's been a robust product for us, primarily due to the detailing the patient services and we think all the RevPARANT service that we provide for patients. Speaker 300:16:27Got it. And then maybe on the new one on Go Like, you're expecting quite a bit of growth there. You already know all of those physicians. How quickly do you think you can kind of get to that 10% penetration level from here? Is it 3 years? Speaker 300:16:45Is it 1 or 2 years? I mean, just kind of help us benchmark kind of how quickly you would expect that growth considering you already know the 100 or so on positions? Speaker 100:16:54Yes. I that's a little more difficult to predict, but we have approximately 50% of that. Let's say, we want to hit $10,000,000 in peak sales, which will be about 10% of the current market. We actually could exceed that depending on how fast the uptake is. There are very few companies out there that are positioned as well as us in terms of being able to promote a PKU product. Speaker 100:17:22So with that said, for us to hit $5,000,000 next year in go like sales is very achievable. It may be significantly higher than that, but I believe that's in the cards. Speaker 300:17:35Got it. That's helpful. And if we kind of think about LKANDI and hydrocortisone portfolio before the ET-four hundred launch, obviously, you're seeing nice growth there still. Do you think there's kind of runway to add another kind of 100 patients from here before ET-four hundred launch or just kind of help benchmark us on kind of growth in alkyndi as we're waiting for ET-four hundred? Speaker 100:17:59Yes. The challenge with the LKINDI is that we it's not a challenge of getting new scripts. So we get a lot of scripts. What happens is some of the patients do not stay on product due to the texture issue that we've mentioned before. So we have a fairly higher rate of discontinuation than I've seen in other pharmaceutical products. Speaker 100:18:21It can be mitigated by education. It can be mitigated by working with the doctors and the caregivers, which we are doing all of those things. And we are planning some additional educational materials to go out to all of the physicians' offices. So when patients are prescribed product, they understand it can be a challenge of texture with the child initially. And I think that for us to have we have growth for the product quarter over quarter. Speaker 100:18:49Can we add another 100 patients? It's not it's certainly an achievable goal, but it's going to hinge largely on reducing the discontinuation rate, which is really the main driver of why we did ET-four hundred in the first place. We look at the reasons why LKINDI patients go off drug and ET-four hundred handles really most of those issues right out of the gate. So I think that is that's why we're really excited about the product. Now that it's been filed, we're already looking to produce and have product even ahead of a 10 month PDUFA date. Speaker 100:19:27So, LKINDI numbers will continue to get scripts week after week. If we can reduce the discontinuations, we can add another 100 patients. If discontinuations are at the same level, it's going to be a little bit more challenging. But it's a robust product and we're going to keep going. Speaker 300:19:47Got it. Maybe shifting gears to AT400 and I just have a couple more guys. Thanks for the time. Maybe speak to us on obviously you've established the PK bridge. Maybe just talk to us on kind of your confidence around the CMC kind of side of that submission. Speaker 300:20:01I mean, are you kind of are you working with a manufacturer who has recently kind of successfully gotten through some FDA audits along the lines of some recent approvals that they are manufacturing? Just kind of talk to us about the confidence of your manufacturing partner there? Speaker 100:20:16Sure. So the files are very similar to what we did with topiramate and zonisomide oral solutions. One of the manufacturers is the same as one of the products, I won't say which one. And so we're confident in their FDA readiness. They have already gone through that process and passed our quality inspections. Speaker 100:20:38So I don't feel the facility has really any risk around it. We feel good about the way the NDA submission has been put together. It's actually been put together at a higher level than what we did for topiramate and zornissomide, both of which are approved in commercial products today. So the process and the deliverables that we had in those files are exactly the same as what we have with ET400. So I really don't see significant barriers to launching the product on time and we'll obviously be very timely in any inquiries we'll get from the FDA and make sure that that process is going smoothly as possible. Speaker 300:21:21And then just last for me, Sean. This is really kind of a line extension with ET-four hundred. You know all these physicians already. You'll obviously be kind of targeting some of those discontinuation patients that ET-four hundred is a great fit with. How quickly should investors be thinking that you can kind of drive scripts with ET-four hundred post launch, just kind of speak to your confidence on how quick that launch can be? Speaker 300:21:46And thanks for taking the time. Speaker 100:21:48Yes, absolutely. Our pleasure. So in terms of the ramp up to what we stated, I think in our press release and in our comments earlier today, it was our goal is to get $50,000,000 plus in revenue between these two products. I feel that within a 12 month timeframe, we'll be well on our way. And I think that getting to that $50,000,000 with the 24 months of launch is achievable. Speaker 100:22:12So that gives you some idea of what how we're thinking on things. Of course, once you get out there, we just did, for example, a panel of doctors of I believe it was 8, maybe it was 10 doctors, who specialize in treating adrenocorticoid insufficiency. And they could not be more excited about this product. There are some of the top prescribers in the nation and so for us to have conversations that just sort of like marketing studies in advance to understand their needs is really important. We want to serve the patients and we believe we've designed a product that will meet patient needs and be well received and prescribed by doctors. Speaker 300:22:58Great. Thanks guys. Speaker 100:23:00You're welcome. Operator00:23:02All right. Thank you. I'm showing no further questions at this time. This does conclude the question and answer session and the program. Thank you for your participation in today's conference. Operator00:23:13You may now disconnect.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallEton Pharmaceuticals Q1 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Eton Pharmaceuticals Earnings Headlines7EYPT : A Peek at EyePoint Pharmaceuticals's Future EarningsMay 6 at 4:04 PM | benzinga.comEton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025May 1, 2025 | globenewswire.comElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.May 6, 2025 | Brownstone Research (Ad)B. Riley Raises Earnings Estimates for Eton PharmaceuticalsMay 1, 2025 | americanbankingnews.comQ1 EPS Estimate for Eton Pharmaceuticals Boosted by AnalystMay 1, 2025 | americanbankingnews.comEton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)April 28, 2025 | globenewswire.comSee More Eton Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Eton Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eton Pharmaceuticals and other key companies, straight to your email. Email Address About Eton PharmaceuticalsEton Pharmaceuticals (NASDAQ:ETON), a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.View Eton Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Palantir Stock Drops Despite Stellar Earnings: What's Next?Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?Is Reddit Stock a Buy, Sell, or Hold After Earnings Release?Warning or Opportunity After Super Micro Computer's EarningsAmazon Earnings: 2 Reasons to Love It, 1 Reason to Be CautiousRocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsMeta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Upcoming Earnings ARM (5/7/2025)AppLovin (5/7/2025)Fortinet (5/7/2025)MercadoLibre (5/7/2025)Cencora (5/7/2025)Carvana (5/7/2025)Walt Disney (5/7/2025)Emerson Electric (5/7/2025)Johnson Controls International (5/7/2025)Lloyds Banking Group (5/7/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 4 speakers on the call. Operator00:00:00Good afternoon, and welcome to the Eaton Pharmaceuticals First Quarter 2024 Financial Results Conference Call. At this time, all participants are in listen only mode. Following the formal remarks, we will open the call up for your questions. Please be advised that this call is being recorded at the company's request. At this time, I'd like to turn it over to David Krimpa, Chief Business Officer at Eton Pharmaceuticals. Operator00:00:27Please proceed. Speaker 100:00:33Thank you, operator. Good afternoon, everyone, and welcome to Eaton's Q1 2024 Conference Call. This afternoon, we issued a press release that outlines the topics we plan to discuss on today's call. The release is available on our website, eatonpharma.com. Joining me on our call today, we have Sean Brynjelsen, our CEO and James Gruber, our CFO. Speaker 100:00:55In addition to taking live questions on today's call, we will be answering questions that are emailed to us. Investors can send their questions to investorrelationseatonpharma.com. Before we begin, I would like to remind everyone that remarks made during this call may contain forward looking statements and involve risks and uncertainties that could cause actual results to differ materially from those contained in these forward looking statements. Please see the forward looking statements disclaimer in our earnings release and the risk factors in the company's filings with the SEC. Now, I will turn the call over to our CEO, Sean Brynjelsen. Speaker 100:01:37Thank you, David. Good afternoon, everyone, and thank you for joining us today. After a strong finish to 2023, I am pleased to say we carry this momentum into 2024 delivering our 13th straight quarter of sequential product revenue growth. It has been a very productive start to 2024 for the company and we have a number of exciting items to discuss today. In addition to posting record revenue sales in Q1, we also acquired a new commercial growth asset in PKU Go Like. Speaker 100:02:08We launched meticinone capsules and more importantly, Eaton submitted our new drug application for ET-four hundred. We were pleased to deliver another quarter of strong revenue growth and to do so while maintaining our disciplined cost structure. Revenue from product sales grew by more than 50% year over year to $8,000,000 while our SG and A spending actually declined by 4% year over year. As you can see, now that we have our infrastructure in place, there was significant operating leverage in our business. We believe we could support a revenue level in many multiples over our current run rate with only a modest increase in our SG and A spending. Speaker 100:02:47This should allow us to deliver substantial earnings as we scale our revenue towards our goal of being a $100,000,000 plus revenue company in the coming years. Our record product sales in the quarter were driven primarily by strong growth in both kaglumic acid and alchemia sprinkle. I remain very encouraged by the trajectory of our kaglumic acid product as it continues to exceed our expectations. We believe we have now captured more than 50% of the patient population, but the product continues to grow and we have added additional patients in Q1 and also additional ones in Q2. Kerglumik is a part of our metabolic portfolio that expanded from 2 products to 4 products in the Q1 as we launched metasalone capsules and acquired PKU Golide. Speaker 100:03:33As you may know, metasalone capsules launched in February and we were able to add a number of patients before the end of the quarter. The market for neticinone is estimated to be around $50,000,000 annually, but there are already a number of competitors in the market, so we have modest expectations for this product. We view the opportunities similar to the way we view Betaine. Neither one offers a large revenue opportunity on its own, but they require very little incremental expense to commercialize since we already have the metabolic infrastructure in place. Perhaps more importantly, the expanded portfolio helps us strengthen our relationship and increase the frequency of interactions with high value kerglumic acid prescribers. Speaker 100:04:15And now with our recent goal like acquisition, natisonone and betaine can help drive additional opportunities to cross sell goal like, which I will spend a few minutes talking about. I was very excited to close this acquisition in March and I believe it adds another compelling growth asset to our metabolic portfolio. Golike is a medical formula for patients with phenylketonuria, also known as PKU. PKU patients like the enzyme needed to break down phenylalanine, which is an amino acid found in protein. For these patients, eating protein results in the buildup of phenylalanine, which can cause neurological problems, including seizures and brain damage. Speaker 100:04:53As a result, many of these PKU patients must take specialized no or low protein medical formulas such as PKU GoLike. Just like our other metabolic products, GoLike is distributed by a specialty distributor that handles dispensing and patient support. The product is typically covered by insurance and it is prescribed by healthcare professionals. I believe GoLike is a compelling opportunity and I'm excited about it for a number of reasons. First, GoLike is very strategic fit with our corporate strategy and commercial infrastructure. Speaker 100:05:26The product serves an ultra orphan population of an estimated 8,000 PKU patients in the United States. These patients rely on medical formulas and the condition is managed by metabolic geneticists and their support staff, the same healthcare professionals that we are actively engaged with on our other metabolic products. Secondly, GoLike is an attractive product that we believe has significant advantages over the competition. Historically, PKU patients have relied on medical providers or medical powders that must be mixed and drank multiple times each day as meal replacements. GOL Like has a number of benefits. Speaker 100:06:02It comes in a convenient and ready to eat bar format. We believe it is significantly is better smelling than competitor products and it is a patented delayed release amino acid technology designed to keep patients full for longer periods of time. And finally, GoLike offered a compelling financial opportunity. We paid less than 2x annual revenue for the product and expect to see significant revenue growth for years to come. Golike Granules were launched at the end of 2022 and Golike Bars were launched in mid-twenty 23. Speaker 100:06:35So the product is still in its infancy stages of launch. We believe our larger commercial footprint and existing relationships with the metabolic community can help accelerate the product's adoption. The U. S. Market for PKU GoLite medical formulas is estimated to be approximately $100,000,000 annually. Speaker 100:06:55With GOL Life's attractive product benefits and our commercial infrastructure, our goal is to capture at least 10% market share or $10,000,000 annually in the coming years. Our sales team launched the product under Eton's ownership at the Metabolic Dieticians International Conference in mid April and we received very strong interest and positive feedback from the dietitian community at the conference. This further reinforced our belief that GoLike provides an improved patient experience and should see significant growth in the years to come as we raise awareness and education in the community. Switching now to the endocrinology side of our business. Alkendi Sprinkle also posted record sales and significant growth in the quarter. Speaker 100:07:38As we discussed in our previous call, we recently introduced a sampling program and our commercial team has been very active at medical conferences so far this year, including exhibiting at the Pediatric Endocrine Society meeting last week. We have seen growth in new patient prescriptions so far and most patients who try Alkindi have a positive experience and remain on therapy. Eaton does however continue to see patients that choose to discontinue treatment due to the texture of the granules. As Okeindi continues to grow, we have a number of initiatives underway to lessen this discontinuation rate, including revamping our educational and administrative materials, but we also believe ET-four hundred will most adequately address this issue. In addition to reducing discontinuation, ET-four hundred will provide an important treatment alternative to the large contingent of patients that use a liquid product today, either a suspension formulation from a compounder that is not FDA approved or their own version that they make at home by crushing tablets and mixing them with water or have been resistant to alkeny sprinkle because they want to stay with a liquid dosage form. Speaker 100:08:44We believe that this portion of the population, which could include several 1,000 patients will be pleased with the accurate dosing in the liquid form that ET-four hundred will provide once it is approved. On our last call, I mentioned that we had passed our clinical study, which was the final hurdle in submission of the ET-four hundred NDA. I am now thrilled to say that we submitted the NDA last week. We anticipate that the FDA will assign the application a 10 month review, allowing for potential approval during the Q1 of 2025. Our team has begun preparing launch activities in order to be in a position to efficiently and effectively commercialize the product shortly after approval. Speaker 100:09:24I remain confident that once approved, the commercialization of ET-four hundred will significantly accelerate the company's growth trajectory and we believe that ET-four hundred and ALK kidney Sprinkle will achieve combined peak sales of over $50,000,000 annually. We also continue to make progress with ET-six hundred, a product candidate under development for the treatment of diabetes ET-six hundred is another new pediatric endocrinology product that we hope to launch soon after ET-four hundred. The product was passed as pilot bioequivalency study and we are on track to run a pivotal study in the second half of this year. Our team expects to submit the NDA in early 2025 for potential approval near the end of 2025. I think it is clear that our 5 commercial products plus our attractive late stage pipeline position us well for sustained long term growth. Speaker 100:10:16That being said, we continue to look for business development opportunities that can propel us even further. Our business development team is currently focused on commercial revenue generating products. Our available capital positions us for a large value creating acquisition. And given our current valuation and expected growth, we would intend to use primarily debt for any such acquisition. As an example of our capacity, in April, we were the runner-up bidder in the bankruptcy auction for Iger Biopharmaceuticals' Zokinbi product. Speaker 100:10:47While we did not we were able to quickly arrange committed capital within a matter of days to support a $46,000,000 bid. While we submitted a competitive offer for the asset, at the end of the day, we are not interested in overpaying for any asset. Given our attractive current financial position, our strong organic growth potential and the expectation for ET-four hundred to deliver significant tailwind next year, we have the luxury of being able to remain extremely disciplined on M and A. While we would like to add a larger asset to the product portfolio, I am cautiously optimistic that we can do so. We certainly do not need to. Speaker 100:11:24Our existing portfolio and pipeline positions us to reach our profitability goals in the coming years. And with that, I'll turn it over to James, our Chief Financial Officer, to to discuss the financials. James? Speaker 200:11:38Thank you, Sean. Our first quarter revenue was 8,000,000 dollars compared to $5,300,000 in the Q1 of 2023, an increase of 50%. In both periods, revenue was comprised entirely of product sales and royalties and the increase was primarily due to increased sales volume of our Arkindi sprinkle and kardalumic acid products. We expect product sales to continue to grow quarter over quarter throughout the rest of this year and beyond. Gross profit for the quarter was $5,000,000 compared with $3,300,000 in the prior year period. Speaker 200:12:16R and D expenses for the quarter were $700,000 compared with $500,000 in the prior year period, and the increase was primarily due to development activities related to ET-four hundred. While we expect an increase in 2nd quarter R and D expenses with a $2,000,000 filing fee for ET-four hundred, we expect total R and D spend for 2024 to remain at approximately 4,000,000 dollars excluding the one time filing fee. General and administrative expenses for the quarter were $5,200,000 compared with $5,300,000 in the prior year period with the decrease due to a slight reduction in employee related expenses and logistics costs. We expect general and administrative expenses to remain relatively constant throughout the remainder of 2024 even with the recent PKU Go Like acquisition and neticinone launch. Total company net loss was $800,000 for the quarter compared to a net loss of $2,700,000 in the prior year period. Speaker 200:13:21Net loss per basic and diluted share was $0.03 during the quarter compared to a net loss per basic and diluted share of $0.10 in the prior year period. Given our current expectations surrounding the timing of R and D activities, we expect to report positive quarterly net income by the end of this year. Eaton finished the Q1 with $16,700,000 of cash on hand and our operating cash burn during the quarter was 2,500,000 dollars While we achieved positive operating cash flow in the second half of twenty twenty three, the Q1 of 2024 was impacted by a one time milestone payment of $1,000,000 related to 2023 al Kindi Sprinkle sales achievement, a payment of $500,000 for inventory associated with the PKU Go Like product acquisition and by the calendarization of marketing and promotion spent that is heavily weighted in the first half of the year. We remain confident that our continued sales growth and disciplined cost structure will result in positive operating cash flow throughout the remainder of 2024 and allow us to actively pursue new product opportunities. This concludes our remarks on Q1 results. Speaker 200:14:39And with that, I'll turn it over to the operator for Q and A. Operator00:14:44Thank you. At this time, we will conduct a question and answer session. First question comes from the line of Chase Knickerbocker of Craig Hallum. Your line is now open. Speaker 300:15:13Good afternoon, guys. Thanks for taking the questions. I'm just going to kind of go product line by product line here. Maybe just to start on Carglumac, Sean. Where are we at in that product's lifecycle? Speaker 300:15:25Do you think we can add a couple handfuls of patients this year still? Or should we think about it as you kind of maintaining the patient volumes that you have, say, in 1Q kind of through this year? Speaker 100:15:39Well, hi, Chase. There's still some runway apparently. We continue to add patients. We just added 3 more patients for the past week. And our estimate is there's up to 100 patients. Speaker 100:15:54We have about a little more than half of that and it continues to grow. We get a lot of new patients on, which actually tend to use that same product over extended period of time. In terms of the product life, it has been robust it's been a robust product for us, primarily due to the detailing the patient services and we think all the RevPARANT service that we provide for patients. Speaker 300:16:27Got it. And then maybe on the new one on Go Like, you're expecting quite a bit of growth there. You already know all of those physicians. How quickly do you think you can kind of get to that 10% penetration level from here? Is it 3 years? Speaker 300:16:45Is it 1 or 2 years? I mean, just kind of help us benchmark kind of how quickly you would expect that growth considering you already know the 100 or so on positions? Speaker 100:16:54Yes. I that's a little more difficult to predict, but we have approximately 50% of that. Let's say, we want to hit $10,000,000 in peak sales, which will be about 10% of the current market. We actually could exceed that depending on how fast the uptake is. There are very few companies out there that are positioned as well as us in terms of being able to promote a PKU product. Speaker 100:17:22So with that said, for us to hit $5,000,000 next year in go like sales is very achievable. It may be significantly higher than that, but I believe that's in the cards. Speaker 300:17:35Got it. That's helpful. And if we kind of think about LKANDI and hydrocortisone portfolio before the ET-four hundred launch, obviously, you're seeing nice growth there still. Do you think there's kind of runway to add another kind of 100 patients from here before ET-four hundred launch or just kind of help benchmark us on kind of growth in alkyndi as we're waiting for ET-four hundred? Speaker 100:17:59Yes. The challenge with the LKINDI is that we it's not a challenge of getting new scripts. So we get a lot of scripts. What happens is some of the patients do not stay on product due to the texture issue that we've mentioned before. So we have a fairly higher rate of discontinuation than I've seen in other pharmaceutical products. Speaker 100:18:21It can be mitigated by education. It can be mitigated by working with the doctors and the caregivers, which we are doing all of those things. And we are planning some additional educational materials to go out to all of the physicians' offices. So when patients are prescribed product, they understand it can be a challenge of texture with the child initially. And I think that for us to have we have growth for the product quarter over quarter. Speaker 100:18:49Can we add another 100 patients? It's not it's certainly an achievable goal, but it's going to hinge largely on reducing the discontinuation rate, which is really the main driver of why we did ET-four hundred in the first place. We look at the reasons why LKINDI patients go off drug and ET-four hundred handles really most of those issues right out of the gate. So I think that is that's why we're really excited about the product. Now that it's been filed, we're already looking to produce and have product even ahead of a 10 month PDUFA date. Speaker 100:19:27So, LKINDI numbers will continue to get scripts week after week. If we can reduce the discontinuations, we can add another 100 patients. If discontinuations are at the same level, it's going to be a little bit more challenging. But it's a robust product and we're going to keep going. Speaker 300:19:47Got it. Maybe shifting gears to AT400 and I just have a couple more guys. Thanks for the time. Maybe speak to us on obviously you've established the PK bridge. Maybe just talk to us on kind of your confidence around the CMC kind of side of that submission. Speaker 300:20:01I mean, are you kind of are you working with a manufacturer who has recently kind of successfully gotten through some FDA audits along the lines of some recent approvals that they are manufacturing? Just kind of talk to us about the confidence of your manufacturing partner there? Speaker 100:20:16Sure. So the files are very similar to what we did with topiramate and zonisomide oral solutions. One of the manufacturers is the same as one of the products, I won't say which one. And so we're confident in their FDA readiness. They have already gone through that process and passed our quality inspections. Speaker 100:20:38So I don't feel the facility has really any risk around it. We feel good about the way the NDA submission has been put together. It's actually been put together at a higher level than what we did for topiramate and zornissomide, both of which are approved in commercial products today. So the process and the deliverables that we had in those files are exactly the same as what we have with ET400. So I really don't see significant barriers to launching the product on time and we'll obviously be very timely in any inquiries we'll get from the FDA and make sure that that process is going smoothly as possible. Speaker 300:21:21And then just last for me, Sean. This is really kind of a line extension with ET-four hundred. You know all these physicians already. You'll obviously be kind of targeting some of those discontinuation patients that ET-four hundred is a great fit with. How quickly should investors be thinking that you can kind of drive scripts with ET-four hundred post launch, just kind of speak to your confidence on how quick that launch can be? Speaker 300:21:46And thanks for taking the time. Speaker 100:21:48Yes, absolutely. Our pleasure. So in terms of the ramp up to what we stated, I think in our press release and in our comments earlier today, it was our goal is to get $50,000,000 plus in revenue between these two products. I feel that within a 12 month timeframe, we'll be well on our way. And I think that getting to that $50,000,000 with the 24 months of launch is achievable. Speaker 100:22:12So that gives you some idea of what how we're thinking on things. Of course, once you get out there, we just did, for example, a panel of doctors of I believe it was 8, maybe it was 10 doctors, who specialize in treating adrenocorticoid insufficiency. And they could not be more excited about this product. There are some of the top prescribers in the nation and so for us to have conversations that just sort of like marketing studies in advance to understand their needs is really important. We want to serve the patients and we believe we've designed a product that will meet patient needs and be well received and prescribed by doctors. Speaker 300:22:58Great. Thanks guys. Speaker 100:23:00You're welcome. Operator00:23:02All right. Thank you. I'm showing no further questions at this time. This does conclude the question and answer session and the program. Thank you for your participation in today's conference. Operator00:23:13You may now disconnect.Read morePowered by